Michael Kreuter

Dec 4, 2024 | bmjopenrespres.bmj.com | Luca Richeldi |Arata Azuma |Vincent Cottin |Michael Kreuter

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease associated with a decline in lung function and early mortality. In a phase II trial, treatment with the oral preferential phosphodiesterase 4B inhibitor, BI 1015550, prevented a decline in lung function over 12 weeks and had an acceptable safety profile in patients with IPF, regardless of background use of antifibrotics, supporting phase III clinical development.

Sep 3, 2024 | erj.ersjournals.com | Jeffrey J Swigris |Paolo Spagnolo |Martin Kolb |Michael Kreuter

FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of Interest: A. Versi has nothing to disclose.

Jun 27, 2024 | bmjopenrespres.bmj.com | Toby Maher |Michael Kreuter |David Lederer |Kevin Brown

Interstitial lung disease Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2) Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service.

Jun 27, 2024 | bmjopenrespres.bmj.com | Luca Richeldi |Arata Azuma |Vincent Cottin |Michael Kreuter

Methods and analysisThis multicentre, double-blind, randomised, placebo-controlled trial is investigating the efficacy and safety of BI 1015550 in patients with IPF stratified by use of background antifibrotics over at least 52 weeks (EudraCT: 1305-0014; ClinicalTrials.gov: NCT05321069). The trial began in September 2022 and is estimated to complete in November 2024.

Jan 1, 2024 | openres.ersjournals.com | Toby Maher |Paul Ford |Michael Kreuter |Kevin Brown

IntroductionIdiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease that places a high burden on patients, with excessive mortality and increasing prevalence [1, 2]. Pirfenidone and nintedanib are approved for the treatment of IPF [3, 4], but neither reverse existing pathology [5–7]. Novel therapeutic agents are under development [8], leading to a pressing need to optimise and standardise clinical trial end-points [9].